BLU-808

DRUG4 trials

Sponsors

Blueprint Medicines Corp., Blueprint Medicines Corporation

Conditions

Allergic RhinoconjunctivitisChronic Inducible UrticariaChronic Inducible Urticaria and Chronic Spontaneous UrticariaChronic Spontaneous UrticariaHealthy Participants

Phase 1

Study of BLU-808 in Healthy Adult Participants

CompletedNCT06948032

Blueprint Medicines CorporationHealthy Participants

Start: 2024-08-07End: 2025-01-21Updated: 2025-04-28

Phase 2

Study of BLU-808 in Allergic Rhinoconjunctivitis

CompletedNCT06922448

Blueprint Medicines CorporationAllergic Rhinoconjunctivitis

Start: 2025-04-14End: 2025-09-08Updated: 2026-02-10

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

RecruitingNCT06931405

Blueprint Medicines CorporationChronic Inducible Urticaria, Chronic Spontaneous Urticaria

Start: 2025-05-28End: 2026-12-31Target: 105Updated: 2026-02-17

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

RecruitingCTIS2024-520031-33-00

Blueprint Medicines Corp.Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

Start: 2025-09-16Target: 57Updated: 2025-09-05